Bookmarks
Optimal dynamic treatment regimes for the management of chronic obstructive pulmonary disease (COPD)
Safe People
Organisation name
McGill University
Organisation sector
Academic Institute
Applicant name(s)
Samy Suissa - Chief Investigator - McGill UniversitySamy Suissa - Corresponding Applicant - McGill UniversityMichael Wallace - Collaborator - University Of WaterlooPierre Ernst - Collaborator - McGill UniversitySophie Dell'Aniello - Collaborator - McGill University
Safe Projects
Project ID
CPRD12
Lay summary
Chronic obstructive pulmonary disease (COPD) is now the third leading cause of death worldwide. Pharmacological treatments for COPD include long-acting bronchodilators and inhaled corticosteroids. These latter medications are associated with some known risks, including pneumonia, while their effectiveness may vary with different patient characteristics, including certain blood markers, asthma, frequent exacerbations and smoking patterns.
Technical summary
Chronic obstructive pulmonary disease (COPD) has become the third leading cause of death worldwide. Long-acting beta2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and inhaled corticosteroids (ICS) are central pharmacologic therapies for COPD. ICS are associated with some known risks, including pneumonia, while their effectiveness appears to vary with different patient characteristics, including blood eosinophil counts, asthma, frequent exacerbations and smoking. We propose to determine the optimal initial and subsequent treatment strategy for COPD, balancing effectiveness and risk, according to specific patient characteristics.
Latest approval date
11/06/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
Safe Setting
Access type
Release